登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)
A Clinical Study Comparing Anti-HER2 Therapy Combined With Chemotherapy to Chemotherapy Alone as Adjuvant Therapy Following Surgery for Stage IB-II Gastric Cancer With High HER2 Expression.
ClinicalTrials.gov 上登记的一项胃癌开放试验,由空军军医大学西京医院牵头,本站收录的另外 0 家医院列为研究中心。
状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月8日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。
研究团队的联系方式见登记记录。本站不转递咨询。
列出这项试验的中国大陆医院 1
登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。
登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心
来源:ClinicalTrials.gov 登记记录 NCT07788196,读取于 2026年11月8日;医院名称与本站医院名单匹配。 名称如何匹配
这项试验的核对清单 6
只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。
展开清单(6 项)收起清单
18 岁 至 未注明;性别:不限
登记记录的入选字段
HER-2-positive (IHC 3+ or IHC 2+ with amplification confirmed by FISH/SISH/CISH);
入选标准第 4 条
Gastric cancer or gastroesophageal junction cancer with TNM stage IB-II;
入选标准第 3 条
Unstable angina, congestive heart failure, or chronic heart failure classified as New York Heart Association (NYHA) Class ≥ 2;
排除标准第 5 条
Patients with a definitive histopathological diagnosis of gastric adenocarcinoma or gastroesophageal junction adenocarcinoma, and an ECOG score ≤ 2;
入选标准第 2 条
Absolute neutrophil count (ANC) ≥ 1.5 × 10⁹/L, without the use of granulocyte colony-stimulating factor (G-CSF) within the past 14 days;
入选标准第 7 条
Platelet count ≥ 100 × 10⁹/L, without a blood transfusion within the past 14 days;
入选标准第 8 条
Hemoglobin > 9 g/dL, without a blood transfusion or the use of erythropoietin within the past 14 days;
入选标准第 9 条
Total bilirubin ≤ 1.5 × upper limit of normal (ULN);
入选标准第 10 条
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 × ULN;
入选标准第 11 条
Serum creatinine ≤ 1.5 × ULN and creatinine clearance (calculated using the Cockcroft-Gault formula) ≥ 60 mL/min;
入选标准第 12 条
Normal coagulation function, defined as an International Normalized Ratio (INR) or prothrombin time (PT) ≤ 1.5 times the ULN;
入选标准第 13 条
Has or has had a malignant tumor in any other part of the body (except for adequately treated cervical carcinoma in situ, basal cell carcinoma of the skin, or other tumors that have been surgically cured and have not recurred for at least 5 years);
排除标准第 3 条
勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:既往治疗;影像与可测量病灶;怀孕、哺乳与避孕。
按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07788196,读取于 2026年11月10日。
登记的入选标准
依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。
入选标准:Inclusion Criteria:
Age ≥ 18 years; Open to all genders; Patients with a definitive histopathological diagnosis of gastric adenocarcinoma or gastroesophageal junction adenocarcinoma, and an ECOG score ≤ 2; Gastric cancer or gastroesophageal junction cancer with TNM stage IB-II; HER-2-positive (IHC 3+ or IHC 2+ with amplification confirmed by FISH/SISH/CISH); Tumor resection has been completed, and adjuvant therapy is planned postoperatively; Adequate organ function; participants must meet the following laboratory criteria: Absolute neutrophil count (ANC) ≥ 1.5 × 10⁹/L, without the use of granulocyte colony-stimulating factor (G-CSF) within the past 14 days; Platelet count ≥ 100 × 10⁹/L, without a blood transfusion within the past 14 days; Hemoglobin > 9 g/dL, without a blood transfusion or the use of erythropoietin within the past 14 days; Total bilirubin ≤ 1.5 × upper limit of normal (ULN); Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 × ULN; Serum creatinine ≤ 1.5 × ULN and creatinine clearance (calculated using the Cockcroft-Gault formula) ≥ 60 mL/min; Normal coagulation function, defined as an International Normalized Ratio (INR) or prothrombin time (PT) ≤ 1.5 times the ULN; Normal thyroid function, defined as thyroid-stimulating hormone (TSH) within the normal range. If baseline TSH is outside the normal range, subjects may still be enrolled provided that total T3 (or FT3) and FT4 are within the normal range; Cardiac enzyme levels are within the normal range (participants with isolated laboratory abnormalities deemed clinically insignificant by the investigator's comprehensive assessment may also be enrolled); Voluntary participation in the study and signing of an informed consent form prior to study initiation.排除标准:Exclusion Criteria:
Other malignant tumors of the stomach; Received, prior to screening, or is scheduled to receive during the trial any anticancer therapy other than the chemotherapy regimen specified in the protocol (e.g., radiation therapy, targeted therapy, immunotherapy); Has or has had a malignant tumor in any other part of the body (except for adequately treated cervical carcinoma in situ, basal cell carcinoma of the skin, or other tumors that have been surgically cured and have not recurred for at least 5 years); Presence of any severe or uncontrolled systemic disease, such as: Unstable angina, congestive heart failure, or chronic heart failure classified as New York Heart Association (NYHA) Class ≥ 2; Significant and symptomatic, difficult-to-control abnormalities in rhythm, conduction, or morphology on a resting electrocardiogram, such as complete left bundle branch block, second-degree or higher heart block, ventricular arrhythmias, or atrial fibrillation; Any arterial thrombosis, embolism, or ischemia occurring within 6 months prior to enrollment, such as myocardial infarction, unstable angina, cerebrovascular accident, or transient ischemic attack; Poorly controlled blood pressure (systolic blood pressure > 150 mmHg, diastolic blood pressure > 100 mmHg); A history of non-infectious pneumonia requiring glucocorticoid therapy within 1 year prior to the first dose, or current clinically active interstitial lung disease; Active pulmonary tuberculosis; Active or uncontrolled infection requiring systemic treatment; Clinically active diverticulitis, intra-abdominal abscess, or gastrointestinal obstruction; Liver disease, such as cirrhosis, decompensated liver disease, or acute or chronic active hepatitis; Poorly controlled diabetes (fasting blood glucose (FBG) > 10 mmol/L); Patients with urine protein ≥++ on urinalysis and confirmed 24-hour urine protein quantification > 1.0 g; Patients with psychiatric disorders who are unable to comply with treatment; Patients currently participating in other clinical trials or who have participated in other clinical trials within the past 3 months; Patients with known allergies to the medications used in this study; Patients deemed unsuitable for participation in this clinical trial by the investigator.
引自 ClinicalTrials.gov, NCT07788196, 参与标准,读取于 2026年11月10日。
这些信息从哪里来
登记记录
ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07788196,读取于 2026年11月8日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。
疾病与医院
本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义
没有收录的内容
登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。